PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. With our ATTEC (autophagosome-tethering compound) technology, we are developing a novel class of small molecule degraders capable of binding a diverse array of substrates to the autophagy pathway including proteins, aggregates, lipids, organelles and pathogens. PAQ’s research advances in this important new class of degradation therapies have the potential to fundamentally transform drug discovery and development.
Company Details
- Employees
- 10
- Address
- 100 Summit Drive, Burlington,ma 01803,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.paqtx.com/
- HQ
- Burlington, MA
Paq Therapeutics Questions
Paq Therapeutics's website is https://www.paqtx.com/
Paq Therapeutics's LinkedIn profile is https://www.linkedin.com/company/paq-therapeutics
Paq Therapeutics has
10 employees.
View email and phone details for 10
employees at Paq Therapeutics.
Paq Therapeutics's industry is
Biotechnology Research
Paq Therapeutics's top competitors are
Recludix Pharma,
Nuevocor,
Solu Therapeutics,
Ranok Therapeutics,
K2b Therapeutics,
Triana Biomedicines,
Inductive Bio,
Kymera Therapeutics,
Newlimit,
Photys Therapeutics.
Paq Therapeutics's categories are Biotechnology Research
